Centene Corporation account plan
Local integrated healthcare plans
At a glance
Centene is a St. Louis managed care company focused on underserved populations, with $194.8 billion of 2025 revenue and 25.9 million members in June 2026.
Centene, headquartered in St. Louis and listed on the NYSE as CNC, runs government-sponsored and commercial health plans through state-based subsidiaries with local brands. It is the largest Medicaid and Marketplace insurer and the largest stand-alone Medicare prescription drug plan provider in the U.S. In FY2025 total revenues were $194.8 billion (+19%), but a $6.7 billion non-cash goodwill impairment led to a net loss attributable to Centene of $(6,674) million; adjusted diluted EPS was $2.08. Membership was 27.6 million at December 31, 2025, served by approximately 61,100 team members.
Business units
Medicaid
57% of 2025 external revenues ($110,434 million total revenues)State Medicaid programmes including TANF, Expansion, Aged/Blind/Disabled, CHIP and long-term services, with 12.5 million members in 30 states at end-2025, the largest Medicaid insurer in the U.S. Margins were hit in 2025 by behavioral health, home health and high-cost drug costs; Q2 2026 gross margin rose 24% on rate increases and cost management.
Commercial
21% of 2025 external revenues ($42,003 million total revenues)The Ambetter Health Marketplace product, the largest Marketplace carrier with 5.5 million members across 29 states at end-2025, plus ICHRA and other off-exchange plans. After a $2.6 billion gross margin drop in 2025, repricing lifted Q2 2026 gross margin to $1,947 million while Marketplace membership fell to 3,494,700.
Medicare
19% of 2025 external revenues ($37,210 million total revenues)Wellcare Medicare Advantage, with 1.0 million members in 32 states and a high concentration of D-SNP dual-eligible members, and the country's largest stand-alone PDP, with 8.1 million members at end-2025. Medicare Advantage is targeted at breakeven or better in 2027.
Other
3% of 2025 external revenues ($5,130 million total revenues)AcariaHealth specialty pharmacy, Magellan Health behavioral health (remaining businesses to be divested), vision and dental programmes, and clinical care through Community Medical Group and Denova Collaborative Health.
Strategic priorities
- Margin restoration
- Corrective 2026 Marketplace pricing in states covering 95% of membership, Medicaid rates matched to post-redetermination acuity, and medical cost management including fraud, waste and abuse detection.
- Dual-eligible integration
- Centene will "place enterprise-level focus on the D-SNP opportunity to drive long-term growth"; D-SNP members are about 40% of Medicare Advantage, and new integrated duals contracts began in Illinois, Ohio and Michigan in January 2026.
- Industry-leading cost structure
- Enterprise optimization simplifies the organisation and operating model through digitisation, AI and voluntary buyouts, with an estimated $480 million midpoint of related SG&A costs in 2026.
- AI on trusted data foundations
- AI work is shifting from use cases to trusted data products, context management and open standards under a strict ROI bar, and finance uses analytics and AI in forecasting, medical economics and payment integrity.
- ICHRA and value-based care
- ICHRA plans expanded from 6 to 13 states in 2026 and reached roughly 50,000 members, and providers are being moved toward shared and full risk arrangements.
Latest results
In Q2 2026 total revenues rose 10% to $53.6 billion and premium and service revenues 4% to $44.4 billion. The health benefits ratio improved to 89.6% from 93.0%, helped by better Marketplace pricing and risk adjustment, Medicaid rate increases and cost management; GAAP diluted EPS was $2.19 and adjusted diluted EPS $2.51. Membership fell 8% year on year to 25.9 million, mainly in the Marketplace. Full-year 2026 adjusted EPS guidance was raised to greater than $4.80 from greater than $3.40, though about $0.50 of Q2 earnings came from 2025 settlements not expected to recur in 2027.
Investments and deals
- Systems capex
- Capex was $767 million in 2025; about $800 million is expected in 2026, mainly system enhancements and computer hardware and software.
- Deleveraging
- $1.3 billion of senior notes were repurchased in H1 2026, partly funded by selling a $1.0 billion interest in 2025 Part D receivables; debt-to-capital fell to 41.6% from 46.5%.
- Magellan Health divestiture
- A definitive agreement to divest the remaining Magellan Health businesses was signed in December 2025, after a $513 million impairment.
- Voluntary separation program
- Accepted on July 27, 2026, with about $315 million to $365 million of severance expected over the rest of 2026.
Challenges and risks
- Medicaid policy changes
- The One Big Beautiful Bill Act brings Medicaid work requirements and more frequent redeterminations largely from 2027; Medicaid membership is expected down 8% to 9% in 2026.
- Marketplace membership and morbidity
- Expiry of enhanced Marketplace subsidies at end-2025 cut membership from 5,541,400 to 3,494,700 by June 2026 and raised the acuity of remaining members.
- Medical cost trend
- Behavioral health remains the largest trend driver, with home health and high-cost drugs, and payment-integrity teams target "AI up-coding".
- Contract losses
- Centene was not selected for Florida Children's Medical Services, its Hawaii Medicaid contracts were not renewed, and about 250,000 California Medi-Cal members leave managed care on January 1, 2027.
What leadership says
“delivering industry-leading health outcomes with an industry-leading cost structure.”
“We aren't just going to deploy AI to talk about AI.”
“this work is not about self-regulating, it's about self disrupting.”
“They saw and called a market-wide issue first.”
Where a supplier can help
- AI with measurable ROI
- Centene is building trusted data products and holds AI to a strict ROI bar; vendors with proven savings in claims, legal or administrative work fit the enterprise optimization priority.
- Payment integrity and fraud detection
- Medical cost management relies on catching inappropriate billing before payment, including AI up-coding, which suits payment-integrity and analytics providers.
- Eligibility and work-requirement support
- OBBBA work requirements and redeterminations push Centene to exchange near real-time data with states and run workforce playbooks, where eligibility, data exchange and community engagement partners can help.
- Dual-eligible care programmes
- The D-SNP focus calls for care coordination, member engagement and value-based care partners in oncology, kidney disease and behavioral health.
- System modernisation
- About $800 million of 2026 capex goes to system enhancements and hardware and software, alongside digitisation under enterprise optimization.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Centene Corporation?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Centene Annual Report on Form 10-K, fiscal year ended December 31, 2025
- Centene (St. Louis, NYSE: CNC) calls itself "the nation's largest managed care company focused on underserved populations": the largest Medicaid and Marketplace insurer and the largest stand-alone Medicare prescription drug plan (PDP) provider. Membership 27.6 million at December 31, 2025; approximately 61,100 team members.
- FY2025 total revenues $194.8 billion (+19%), premium and service revenues $174.6 billion (+20%); health benefits ratio (HBR) 91.9% vs 88.3%; SG&A ratio 7.4% vs 8.5%; operating cash flow $5.1 billion.
- A hard year: a $6.7 billion non-cash goodwill impairment drove a GAAP diluted loss per share of $(13.53); adjusted diluted EPS $2.08 vs $7.17 in 2024.
- Four segments by share of external revenues: Medicaid 57% (12.5 million members in 30 states), Commercial 21% (Ambetter Health Marketplace, 5.5 million members in 29 states), Medicare 19% (Wellcare: 1.0 million Medicare Advantage members in 32 states, 8.1 million PDP members) and Other 3% (AcariaHealth specialty pharmacy, Magellan Health, vision and dental, clinical care).
- 2025 pressure points: lower Marketplace risk adjustment revenue after data showed "significantly higher estimated aggregate market morbidity", plus higher Medicaid costs in behavioral health, home health and high-cost drugs; Commercial gross margin fell $2.6 billion.
- Responses: corrective 2026 Marketplace pricing in states covering 95% of membership; Medicare Advantage refocused on D-SNP duals (membership down 10%); ICHRA off-exchange plans expanded from 6 to 13 states in 2026; remaining Magellan Health businesses to be divested ($513 million impairment).
- Policy headwinds: the One Big Beautiful Bill Act (Medicaid work requirements and more frequent redeterminations largely from 2027, provider-tax and state-directed-payment changes from 2028), expiry of enhanced Marketplace subsidies at end-2025, IRA changes to Part D.
- 2026 expectations in the filing: about $800 million of capex (system enhancements, hardware and software) and about $1.2 billion of net dividends from regulated subsidiaries; debt-to-capital 46.5%; $1.8 billion left on the buyback authorisation.
- Centene Quarterly Report on Form 10-Q for Q2 2026 (quarter ended June 30, 2026)
- Q2 2026 total revenues $53.6 billion (+10%), premium and service revenues $44.4 billion (+4%); HBR 89.6% vs 93.0%; adjusted SG&A ratio 6.9% vs 7.1%.
- GAAP diluted EPS $2.19 (vs a $(0.51) loss in Q2 2025) and adjusted diluted EPS $2.51; first-half GAAP diluted EPS $5.30.
- Managed care membership 25.9 million, down 2.1 million (8%) year on year: Medicaid 12,110,700, Marketplace 3,494,700 (from 5,862,800), PDP 8,803,000, Medicare 980,000.
- Commercial gross margin more than doubled to $1,947 million on repricing and risk adjustment; final 2025 Marketplace risk adjustment gave a $481 million pre-tax benefit. Medicare gross margin +35%, Medicaid +24%.
- Enterprise optimization: a voluntary separation program accepted July 27, 2026, with about $315 million to $365 million of severance expected over the rest of 2026.
- Deleveraging: $1.3 billion of senior notes repurchased in H1 (partly funded by selling $1.0 billion of 2025 Part D receivables); debt-to-capital down to 41.6% from 46.5%.
- Upcoming headwinds: about 250,000 California Medi-Cal UIS members leave managed care on January 1, 2027; Hawaii Medicaid contracts not renewed; Florida CMS contract ends September 2026. Wins: Illinois HealthChoice Medicaid contract from January 2027.
- Centene Q2 2026 earnings call transcript (Sarah London, CEO; Drew Asher, CFO)
- London framed Q2 as progress on "margin restoration": adjusted EPS $2.51 beat expectations and full-year 2026 adjusted EPS guidance rose to greater than $4.80 from greater than $3.40; Asher flagged about $0.50 of 2025 settlements that will not recur in 2027.
- Marketplace (Ambetter) is the swing factor: HBR 79.2% vs 90.6%; pretax margin now expected at 4.5% to 5% (prior 3%), after the June Wakely data confirmed higher-acuity Silver members and $180 million of favourable 2025 risk adjustment.
- Medicaid on plan at a 93.9% Q2 HBR, full-year target about 93.5%; 2026 composite rate now about 5% (from 4.5%); membership expected down 8% to 9% for the year as states tighten eligibility ahead of OBBBA ("OB3") work requirements.
- Medicare: PDP pretax margin now greater than 3% (guided 2%) on about $25 billion of premium revenue; D-SNP is about 40% of Medicare Advantage; MA targeted at "breakeven or better results in 2027", with a simplified 2027 footprint focused on duals.
- Pharmacy scale: more than $60 billion of pharmacy spend leveraged through the partnership with ESI.
- Enterprise optimization: organisation simplification, voluntary buyouts, about $480 million midpoint of related SG&A costs in 2026; ambition of "industry-leading health outcomes with an industry-leading cost structure".
- AI: shifting from use cases to foundations (trusted data products, context management, open standards) with a strict ROI bar; a legal-invoice review agent saves 1.5 points on legal bills.
- ICHRA about 50,000 members, 2.5x a year earlier.
- Centene Q1 2026 earnings call transcript (Sarah London, CEO; Drew Asher, CFO)
- Q1 2026 adjusted diluted EPS $3.37 beat plan; full-year adjusted EPS guidance raised to greater than $3.40 from greater than $3, with a "prudent outlook" for the rest of the year.
- Medicaid HBR 93.1% (50 basis points better year on year), third consecutive quarter of progress; net trend assumed mid-4% and composite rate yield about 4.5%; ABA trends stabilising after fraud, waste and abuse work.
- Medicare HBR 84.9%, both Medicare Advantage and PDP ahead; D-SNP members now 40% of MA; path to MA breakeven in 2027; PDP ended Q1 with just over 8.7 million members.
- Marketplace: just under 3.6 million members (about half Silver, roughly 35% Bronze); higher Silver utilisation expected to earn a risk adjustment offset; pretax margin guided around 3% pending June Wakely data. Centene initiated an earlier industry demographic report with Wakely.
- New leadership structure: Dan Finke joined as Group President for Medicaid and Commercial; Michael Carson elevated to Group President for Medicare, PDP and Specialty.
- Balance sheet: $1 billion of 2025 Part D receivables sold to repurchase $1 billion of notes; debt-to-capital 43.2%; operating cash flow $4.4 billion.
- RFP pipeline: a lighter procurement year, but states (e.g. Indiana) consolidating reprocurements and considering carving higher-acuity populations into managed care.
Questions about Centene Corporation
What does Centene do?
Centene is a managed care company focused on underserved populations. It runs Medicaid, Marketplace (Ambetter Health) and Medicare (Wellcare and stand-alone drug plans) health plans through state-based subsidiaries.
What is Centene's revenue?
Total revenues were $194.8 billion in FY2025, up 19%. In Q2 2026 total revenues were $53.6 billion, up 10%.
How many employees and members does Centene have?
Centene had approximately 61,100 team members and 27.6 million members at December 31, 2025; membership was 25.9 million at June 30, 2026.
What is Centene's strategy?
It is restoring margins through repricing and medical cost management, focusing Medicare on dual-eligible D-SNP members, simplifying the organisation, and growing ICHRA products.
Who leads Centene?
Sarah M. London has been CEO since March 2022, with Andrew L. Asher as EVP and CFO and Susan R. Smith as COO.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)